Citrate and celecoxib induce apoptosis and decrease necrosis in synergistic manner in canine mammary tumor cells

Cellular and Molecular Biology

Volumn 61, Issue 5, 2015, Pages 22-28

  Vahidi, R ^a   Safi, Shahabeddin ^a   Farsinejad, A ^b   Panahi, N ^a  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Canine mammary tumors; Celecoxib; Citrate

Indexed keywords

CELECOXIB; CITRIC ACID; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; BREAST TUMOR; CANCER INHIBITION; CELL ADHESION; CELL PROLIFERATION; CELL VIABILITY; CF41 MG CELL LINE; CONTROLLED STUDY; DRUG POTENTIATION; IC50; IMMUNOCYTOCHEMISTRY; NECROSIS; NONHUMAN; SPINDLE CELL; ANIMAL; CELL SURVIVAL; DISEASE MODEL; DOG; DRUG EFFECTS; FEMALE; MAMMARY NEOPLASMS, ANIMAL; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELECOXIB; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CITRATES; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DOGS; DRUG SYNERGISM; FEMALE; MAMMARY NEOPLASMS, ANIMAL; NECROSIS;

EID: 84963706972     PISSN: 01455680     EISSN: 1165158X     Source Type: Journal    
DOI: 10.14715/cmb/2015.61.5.4     Document Type: Article

References (49)

1. Saito T, Dai T, Asano R., The hyaluronan synthesis inhibitor 4-methylumbelliferone exhibits antitumor effects against mesenchymal-like canine mammary tumor cells. Oncology letters. 2013, 5(3):1068-74. doi:10.3892/ol.2013.1124
2. Icard P, Poulain L, Lincet H., Understanding the central role of citrate in the metabolism of cancer cells. Biochimica et biophysica acta. 2012, 1825(1):111-6. doi: 10.1016/j.bbcan.2011.10.007
3. Cairns RA, Harris IS, Mak TW., Regulation of cancer cell metabolism. Nature reviews Cancer. 2011, 11(2):85-95. doi: 10.1038/nrc2981
4. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB., Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev. 2008, 18(1):54-61. doi: 10.1016/j.gde.2008.02.003
5. Vander Heiden MG., Targeting cancer metabolism: a therapeutic window opens. Nature reviews Drug discovery. 2011, 10(9):671-84. doi: 10.1038/nrd3504
6. de Groot DJ, de Vries EG, Groen HJ, de Jong S., Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol. 2007, 61(1):52-69. doi: 10.1016/j.critrevonc.2006.07.001
7. Thun MJ, Henley SJ, Patrono C., Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. Journal of the National Cancer Institute. 2002, 94(4):252-66. doi:10.1093/jnci/94.4252
8. Anderson WF, Umar A, Viner JL, Hawk ET., The role of cyclooxygenase inhibitors in cancer prevention. Curr Pharm Des. 2002, 8(12):1035-62. doi:10.2174/1381612023394935
9. Dai ZJ, Ma XB, Kang HF, Gao J, Min WL, Guan HT, Diao Y, Lu WF, Wang XJ., Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo. Cancer Cell Int. 2012, 12(1):53. doi: 10.1186/1475-2867-12-53
10. Awara WM, El-Sisi AE, El-Sayad ME, Goda AE., The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? Pharmacological research. 2004, 50(5):487-98. doi:10.1186/1475-2867-12-53
11. Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW., Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther. 2008, 7(4):897-904. doi: 10.1158/1535-7163.MCT-07-0313
12. Brunelle M, Sartin EA, Wolfe LG, Sirois J, Dore M., Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines. Veterinary pathology. 2006, 43(5):656-66. doi: 10.1354/vp.43-5-656
13. Dore M., Cyclooxygenase-2 expression in animal cancers. Veterinary pathology. 2011, 48(1):254-65. doi: 10.1177/0300985810379434
14. Bocca C, Bozzo F, Bassignana A, Miglietta A., Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem. 2011, 350(1-2):59-70. doi: 10.1007/s11010-010-0682-4
15. Ding H, Han C, Zhu J, Chen CS, D'Ambrosio SM., Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9. International journal of cancer Journal international du cancer. 2005, 113(5):803-10. doi: 10.1002/ijc.20639
16. Grosch S, Maier TJ, Schiffmann S, Geisslinger G., Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006, 98(11):736-47. doi: 10.1093/jnci/djj206
17. Zhang H, Ye YJ, Bai ZG, Wang S., The COX-2 selective inhibitor-independent COX-2 effect on colon carcinoma cells is associated with the Delta1/Notch1 pathway. Digestive diseases and sciences. 2008, 53(8):2195-203. doi: 10.1007/s10620-007-0139-0
18. Tegeder I, Pfeilschifter J, Geisslinger G., Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2001, 15(12):2057-72. doi: 10.1096/fj.01-0390rev
19. Queiroga FL, Raposo T, Carvalho MI, Prada J, Pires I., Canine Mammary Tumours as a Model to Study Human Breast Cancer: Most Recent Findings. in vivo. 2011, 25(3):455-65.
20. Sorenmo KU, Kristiansen VM, Cofone MA, Shofer FS, Breen AM, Langeland M, Mongil CM, Grondahl AM, Teige J, Goldschmidt MH., Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence. Vet Comp Oncol. 2009, 7(3):162-72. doi: 10.1111/j.1476-5829.2009.00184.x
21. Torres CG, Olivares A, Stoore C., Simvastatin exhibits antiproliferative effects on spheres derived from canine mammary carcinoma cells. Oncol Rep. 2015, 33(5):2235-44. doi: 10.3892/or.2015.3850
22. Freshney RI., Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications. 6th ed: John Wiley & Sons; 2010. p. 387-403. doi: 10.1002/9780470649367
23. Elmore S., Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007, 35(4):495-516. 10. doi:1080/01926230701320337
24. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP., Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry. 1998, 31(1):1-9. doi: 10.1177/002215549904700901
25. Stefanou D, Batistatou A, Nonni A, Arkoumani E, Agnantis NJ., p63 expression benign and malignant breast lesions. Histol Histopathol. 2004, 19(2):465-71.
26. Gama A, Alves A, Gartner F, Schmitt F., p63: a novel myoepithelial cell marker in canine mammary tissues. Veterinary pathology. 2003, 40(4):412-20. doi: 10.1354/vp.40-4-412
27. Gama A., A novel myoepithelial cell marker in canine mammary tissue. Vet J. 2011, 190(3):303-4. doi: 10.1016/j.tvjl.2011.04.016
28. Zuccari DA, Pavam MV, Terzian CB, Pereira RS, Ruiz CM, Andrade JC., Immunohistochemical evaluation of e-cadherin, Ki-67 and PCNA in canine mammary neoplasias: correlation of prognostic factors and clinical outcome. Pesquisa Veterinária Brasileira. 2008, 28(4):207-15. doi: 10.1590/so100-736/2008000
29. Martinez-Arribas F, Alvarez T, Del Val G, Martin-Garabato E, Nunoz-Villar MJ, Lucas R, Sanchez J, Tejerina A, Schneider J., Bcl-2 expression in breast cancer: A comparative study at the mRNA and protein level. Anticancer research. 2007, 27(1A):219-22. doi: 10.1371/journal.pone.0000216
30. Youle RJ, Strasser A., The BCL-2 protein family: opposing activities that mediate cell death. Nature reviews Molecular cell biology. 2008, 9(1):47-59. doi: 10.1038/nrm2308
31. Knowlton K, Mancini M, Creason S, Morales C, Hockenbery D, Anderson BO., Bcl-2 slows in vitro breast cancer growth despite its antiapoptotic effect. The Journal of surgical research. 1998, 76(1):22-6. doi: 10.1006/jsre.1998.5277
32. Lu Y, Zhang X, Zhang H, Lan J, Huang G, Varin E, Lincet H, Poulain L, Icard P., Citrate induces apoptotic cell death: a promising way to treat gastric carcinoma? Anticancer Res. 2011, 31(3):797-805.
33. Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P., Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis. J Exp Med. 1997, 185(8):1481-6. doi: 10.1084/jem.185.8.1481
34. Waskewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J., Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 2002, 62(7):2029-33.
35. Zhang GS, Liu DS, Dai CW, Li RJ., Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Am J Hematol. 2006, 81(4):242-55. doi: 10.1002/ajh.20542
36. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A., Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol. 2009, 48(6):811-21. doi: 10.1080/02841860902974175
37. Ustun Alkan F, Ustuner O, Bakirel T, Cinar S, Erten G, Deniz G., The effects of piroxicam and deracoxib on canine mammary tumour cell line. The Scientific World Journal. 2012, 2012:976740. doi: 10.1100/2012/976740
38. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P., Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res. 2005, 7(4):R422-35. doi: 10.1186/bcr1019
39. Kundu N, Smyth MJ, Samsel L, Fulton AM., Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Treat. 2002, 76(1):57-64.
40. Mutsaers A, Mohammed S, DeNicola D, Snyder P, Glickman N, Bennett P, De Gortari A, Bonney P, Knapp D., Pretreatment tumor prostaglandin E 2 concentration and cyclooxygenase-2 expression are not associated with the response of canine naturally occurring invasive urinary bladder cancer to cyclooxygenase inhibitor therapy. Prostaglandins, leukotrienes and essential fatty acids. 2005, 72(3):181-6. doi: 10.1016/i-plefa
41. Zhang X, Varin E, Allouche S, Lu Y, Poulain L, Icard P., Effect of citrate on malignant pleural mesothelioma cells: a synergistic effect with cisplatin. Anticancer Res. 2009, 29(4):1249-54.
42. Kruspig B, Nilchian A, Orrenius S, Zhivotovsky B, Gogvadze V., Citrate kills tumor cells through activation of apical caspases. Cellular and Molecular Life Sciences. 2012, 69(24):4229-37. doi: 10.1007/s00018-012-1166-3
43. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subbaramaiah K, Pasmantier MW, Dannenberg AJ., Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003, 21(14):2645-50. doi: 10.1200/JCO.2003.07.127
44. Fantappie O, Solazzo M, Lasagna N, Platini F, Tessitore L, Mazzanti R., P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res. 2007, 67(10):4915-23. doi: 10.1158/0008-5472.CAN-06-3952
45. Zatelli MC, Luchin A, Tagliati F, Leoni S, Piccin D, Bondanelli M, Rossi R, degli Uberti EC., Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer. 2007, 14(4):1029-38. doi: 10.1677/ERC-07-0114
46. Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, Reddanna P., Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk Res. 2008, 32(6):855-64. Doi: 10.1016/j.leukres.2007.11.007
47. Bassiouny AR, Zaky A, Neenaa HM., Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients. Ann Hepatol. 2010, 9(4):410-8.
48. Chen C, Shen HL, Yang J, Chen QY, Xu WL., Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. J Cancer Res Clin Oncol. 2011, 137(1):9-17. doi: 10.1007/s00432-010-0854-3
49. Lee JY, Tanabe S, Shimohira H, Kobayashi Y, Oomachi T, Azuma S, Ogihara K, Inokuma H., Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma. Res Vet Sci. 2007, 83(2):210-6. doi: 10.1016/j.rvsc.2006.12.012